hiv 1 p17 p24 gp120 fusion protein  (Jena Bioscience)

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: Identification of H5N1 peptides for serodiagnosis of H5N1 infection using a gene fragment phage display library. (A) The 11 proteins encoded by eight RNA segments in the H5N1 virus are depicted. Alignment of H5N1 sequences displayed on the affinity-selected phage clones after the second round of panning with the H5N1 genome sequence (H5N1 A/Vietnam/1203/2004) led to identification of the immunodominant regions recognized by antibodies generated after H5N1 infection in PB1-F2, HA2, and M2e. (B) Sequence alignment of selected peptides in PB1-F2, HA2, and M2e that are being used in H5N1-SeroDetect with other H5N1 strains from different clades and seasonal influenza virus strains is shown. The numbers in each epitopic site indicate the positions of the amino acid residues in the corresponding H5N1-encoded proteins for the A/Vietnam/1203/2004 strain.

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Infection, Virus, Clone Assay, Sequencing, Generated

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: Seroreactivity of H5N1-negative samples with H5N1-SeroDetect peptides and determination of cutoff values. ELISA conditions were described in Materials and Methods. (A to C) Reactivities of 139 H5N1-seronegative serum/plasma samples from the United States and Vietnam at a 1:100 dilution with the peptides HA2 (488–516) (A), PB1-F2 (2–75) (B), and M2e (2–24) (C) peptides are shown. Values on the x axis are the test specimen ODs with the H5N1 peptide in specific ELISA. The y axis represents the number of serum/plasma samples that exhibited a specific ELISA absorbance reading as shown on the x axis. (D) The cutoff value for each peptide was determined as the mean absorbance + 5 standard deviations obtained with H5N1-seronegative samples.

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Enzyme-linked Immunosorbent Assay, Clinical Proteomics

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: H5N1-SeroDetect reactivities of control and post-H5N1 infection human sera

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Control, Infection, Enzyme-linked Immunosorbent Assay

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: Summary of H5N1-SeroDetect specificity: no reactivity with serum samples from individuals vaccinated with H5N1 vaccine or individuals with seasonal influenza virus vaccination and infections

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Virus, Enzyme-linked Immunosorbent Assay, Infection

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: H5N1-SeroDetect ELISA reacts with H5N1 serum panels at early time points postinfection from nonsurvivors. Reactivity in the H5N1-SeroDetect ELISA of sequential plasma samples obtained soon after acute infection from individuals who succumbed to H5N1 (clade 2.3.4) infection in Vietnam. Reactivities of two representative sequential samples, one female (aged 20 years) and one male (aged 30 years), with HA2 (488–516) (A), PB1-F2 (2–75) (B), and M2e (2–24) (C) peptides are shown. In these panels, all plasma samples were tested at a 1:100 dilution. All data are represented as test specimen ODs on the y axis. Day 0 represents the date of onset of symptoms. The upper and lower limits for the average cutoff values + 5 standard deviations of the plasma sample upon repeated testing, representing the 95% confidence intervals for the given sample, ranged from 0.09 to 0.11 for each of the three peptides. The cutoff value for each peptide is shown as a dashed line in each graph.

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Infection

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: Seroreactivity of H5N1 seroconversion panels in H5N1-SeroDetect ELISA soon after infection in H5N1 survivors. Sequential plasma samples obtained soon after acute infection up to 2 months from individuals who survived H5N1 (clade 2.3.4) infection in Vietnam were tested in the H5N1-SeroDetect. Reactivities of two representative sequential samples from males (aged 21 and 30 years) with HA2 (488–516) (A), PB1-F2 (2–75) (B), and M2e (2–24) (C) peptides. All plasma samples were tested at a 1:100 dilution. All data are represented as test specimen ODs on the y axis. The cutoff value for each peptide was determined as the mean absorbance + 5 standard deviations obtained with H5N1-seronegative samples (Fig. 2) and was <0.11 for each of the three peptides. The cutoff value for each peptide is shown as a dashed line in each graph.

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Enzyme-linked Immunosorbent Assay, Infection, Clinical Proteomics

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: Summary of H5N1-SeroDetect ELISA with H5N1 virus-infected serum samples

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Enzyme-linked Immunosorbent Assay, Virus

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: H5N1-SeroDetect detects long-lasting H5N1-specific antibodies up to 4 years following recovery from H5N1 infection. Long-term follow-up of sequential plasma samples obtained after 2 months and up to 4 years post-H5N1 infection from individuals who survived H5N1 (clade 1) infection in Vietnam tested in the H5N1-SeroDetect. Reactivities of three representative sequential samples (at a 1:100 dilution) with HA2 (488–516) (A), PB1-F2 (2–75) (B), and M2e (2–24) (C) peptides are shown. All data are represented as test specimen ODs on the y axis. In all three H5N1-infected individuals, the H5N1-SeroDetect was positive (OD > respective cutoff value) with at least one of the three peptides from the earliest bleed. The cutoff value for each peptide is shown as a dashed line in each graph.

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Infection, Clinical Proteomics

Journal: Journal of Virology

Article Title: H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance ^▿ †

doi: 10.1128/JVI.06023-11

Figure Lengend Snippet: H5N1-SeroDetect rapid test for detection of H5N1 infections. (A) The rapid test was developed by striping H5N1 peptides [HA2 (488–516), PB1-F2 (2–75), and M2e (2–24)] and control protein (goat anti-human IgG), and data were assessed using a panel of H5N1 patient and control plasma samples at a 1:50 dilution. H5N1 virus-infected samples were from the survivors (clade 1 and clade 2.3.4) and individuals who died from infection (clade 2.3.4) in Vietnam. (B) Summary of reactivities of H5N1-negative and H5N1-positive samples in rapid assay format of H5N1-SeroDetect. Combined reactivity depicts positivity to any one or more antigens in the H5N1-SeroDetect. In all the H5N1 virus-infected individuals, the H5N1-SeroDetect rapid test was positive with at least one of the peptides.

Article Snippet: For the H5N1 vaccine study, inactivated unadjuvanted subunit H5N1 vaccine for the clade −1 H5N1 strain (rgA/Vietnam/1203/04 × A/PR/8/34) that contained 90 or 120 μg/ml hemagglutinin (HA) was used as a vaccine (Sanofi Pasteur) ( 1 ).

Techniques: Control, Clinical Proteomics, Virus, Infection